IRCT20150303021315N16招募中4 期
Post-marketing surveillance for evaluation of AryoTrust safety in Iranian HER2-positive breast cancer patients under adjuvant chemotherapy regimens
Aryogen0 个研究点目标入组 597 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 597
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients diagnosed with non-metastatic HER2 positive breast cancer after treatment with adjuvant chemotherapy (trastuzumab in combination with doxetaxel or paclitaxel weekly for 12 weeks or others regimens) who are candidates for trastuzumab maintenance therapy 6 mg/kg every 3 weeks for 12 months
排除标准
- •-Patients who received Herceptin
- •-Patients who are not candidates for trastuzumab maintenance therapy after adjuvant chemotherapy
研究者
相似试验
尚未招募
4 期
A post-marketing surveillance for the Evaluation of the safety of TGlobulin25 for the induction of immunosuppressive therapy in adult kidney transplant candidatesIRCT20201230049888N1Kawsar biotech company100
已完成
不适用
AryoTrust® (Trastuzumab) Safety StudyBreast CancerNCT06021379AryoGen Pharmed Co.597
已完成
4 期
A study of Pregabalin IP 75 mg and Nortriptyline 10 mg Tablets in patients with diabetic peripheral neuropathyCTRI/2022/02/040438Micro Labs Limited203
招募中
4 期
A Post-Marketing Surveillance Study to assess the safety and efficacy of Cetuximab plus Radiotherapy (RT) in Locally Advanced Squamous Cell Carcinoma of Head & Neck (LA SCCHN)CTRI/2011/091/000206Merck Specialities Pvt Ltd200
已完成
4 期
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of basic Fibroblast Growth Factor Compared to Placebo in Combination with NBUVB for the Treatment of VitiligoIRCT20201104049265N1Imen Vaccine Alborz88